Current findings revealed that VRSO and VRPO treatment markedly decreased the mRNA expression of IL-1α and IL-1β and therefore decreased the neuroinflammation and accumulation of β-amyloids significantly in treated groups compared to AD like phenotype group. The gene discussed is IL1A; the disease is Alzheimer disease.